reports
Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Dir...
Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creation CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the “Board”), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experie...
Dentsply Sirona and Burkhart Dental Supply Announce Expanded Distribut...
Dentsply Sirona and Burkhart Dental Supply Announce Expanded Distribution Partnership to Include Dental Technology Equipment As of April 1, Burkhart Dental Supply will represent Dentsply Sirona’s full portfolio of dental technology solutions in addition to preventive and restorative solutions it already distributes. The expanded partnership is designed to give dental professionals more comprehensive access to the tools they rely on every day, combining digital technologies, clinical products, and local support to help practices streamline workflows and adopt new technology with confidence. ...
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update --Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Medicare Part D Milestone: We are ple...
Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call o...
Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26 CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourth quarter and full year 2025 financial results. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company’s website at...
Patterson Dental and Dentsply Sirona Renew U.S. Dental Technology Dist...
Patterson Dental and Dentsply Sirona Renew U.S. Dental Technology Distribution Partnership The renewed agreement marks a strategic step toward accelerating growth and expanding access to integrated, high-quality dental technology solutions that help dental professionals elevate patient care CHARLOTTE, N.C., Jan. 14, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, and Patterson Dental Holdings (“Patterson Dental”), a leading supplier of products and services to...
Dentsply Sirona and Benco Dental Announce Expanded Partnership to Incl...
Dentsply Sirona and Benco Dental Announce Expanded Partnership to Include Dental Technology Solutions Benco Dental will offer Dentsply Sirona’s full portfolio of dental technology solutions, in addition to the consumables portfolio. Expanding the decades-long relationship reflects a shared vision to advance by facilitating access to an integrated ecosystem that connects devices, software, and people—from scanning to designing and manufacturing—for greater efficiency and better patient outcomes. CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (...
Dentsply Sirona Appoints Donald Zurbay to Board of Directors
Dentsply Sirona Appoints Donald Zurbay to Board of Directors Company’s Board of Directors forms Growth and Value Creation Committee to guide the Company’s Return-to-Growth Action Plan CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the “Board”), effective January 10, 2026. He will be joining the Board’s Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value...
Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Ameri...
Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona’s continued focus on strengthening commercial execution, deepening customer relationsh...
Dentsply Sirona to Present at the 44th Annual J.P. Morgan Healthcare C...
Dentsply Sirona to Present at the 44th Annual J.P. Morgan Healthcare Conference CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT (6:00 p.m. ET). During the presentation, Dan Scavilla, President and CEO of Dentsply Sirona, will provide an update on the Company's differentiated Connected Dentistry portfolio, dental market trends and the Company’s progres...
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update Expanded Market Access for ORLYNVAHTM DUBLIN and CHICAGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™’s market access continues to accelerate. We have final...
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™’s market access continues to accelerate. We have finalized a commercial contract with a Group ...
Dentsply Sirona Declares Quarterly Cash Dividend
Dentsply Sirona Declares Quarterly Cash Dividend CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of December 26, 2025. About Dentsply Sirona Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and se...
Dentsply Sirona Inc: 1 director
A director at Dentsply Sirona Inc sold 82,200 shares at 11.140USD and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Expanding Reimbursement Footprint: ORLYNVAH™’s access continues to grow—both with and without prior authorization or medical exception pathways, allowing coverage approval fo...
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update DUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Specialty Distributor Now Stocked: ORLYNVAH™ is now available at McKesson, which will allow certain physicians the ability to procure the product directly from McKesson through this specialty dis...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FAST FASTENAL COMPANY
CVBF CVB FINANCIAL CORP.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CDXS CODEXIS
ASPN ASPEN AEROGELS
WHF WHITEFIELD
FMC FMC CORPORATION
AMCR AMCOR PLC
NLOK NORTONLIFELOCK INC.
AVO MISSION PRODUCE
ACVA ACV AUCTIONS INC.
TBBK THE BANCORP
SPRU INC.
HYMC SPRUCE POWER HOLDING CORP
RMI HYCROFT MINING HOLDING CORPORATION
RIVERNORTH OPPOR MUN INC FD INC
Iterum Therapeutics Reports Third Quarter 2025 Financial Results
Iterum Therapeutics Reports Third Quarter 2025 Financial Results --Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended Septemb...
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on ...
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a....
Dentsply Sirona Reports Third Quarter 2025 Results
Dentsply Sirona Reports Third Quarter 2025 Results Dentsply Sirona Reports Third Quarter 2025 Results Net sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buyGAAP gross margin of 48.8%, GAAP net loss per share of ($2.14)Adjusted gross margin of 52.6%, adjusted EBITDA margin of 18.4%, adjusted EPS of $0.37Revised FY25 outlook Executing its Return-to-Growth action plan to drive improved performance and deliver sustained, profitable growthProvides leadership updates to support transformation st...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.